AstraZeneca (NASDAQ: AZN) has had a rough couple of weeks. Several European countries including France and Germany suspended use of the company’s coronavirus vaccine. They cited risk of dangerous blood clots. But AstraZeneca’s situation improved in recent days. The countries reversed their decisions — and resumed vaccinations with the AstraZeneca product. In more good news, AstraZeneca reported positive results from its phase 3 U.S. trial. The company now says it’s preparing to request Emergency Use Authorization (EUA) in the U.S.
But two elements may upset the AstraZeneca vaccine’s future in the U.S. market. Let’s take a closer look at each — and what all of this means for investors in this big pharma stock.